• First simultaneous LC-MS/MS method for quantifying 11dH-TXB2 and creatinine in urine, reducing workload and sample volume.
• Enables accurate monitoring of aspirin-induced platelet inhibition via 11dH-TXB2/creatinine ratio.
• Validated with low, medium, and high concentration quality controls using a blank urine matrix.
• Provides a standardized approach for clinical research and methodology optimization.